The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases
https://doi.org/10.18087/cardio.2019.4.10251
Abstract
Understanding mechanisms of chemotherapy cardiotoxicity is an important problem due to the lack of clear understanding of its occurrence. Development of endothelial dysfunction is considered to be one of possible ways in implementation of these side effects. The analysis of endothelin-1 and e-selectin levels in 26 patients with lymphoproliferative diseases before and after the completion of the treatment program was been performed. The results of the study showed normal values of E-selectin level and increased level of endothelin-1 in the whole group of patients before treatment. After completion of chemotherapy program, in the whole group, there was a decrease of these two markers. However, values of level of endothelin-1 with vasoconstrictor effect remained high even after the end of therapy. It is imp ortant that at detailed analysis the dynamics of investigated markers in patients of older age group (median age 64 years) was associated with worsening of endothelial dysfunction.
About the Authors
D. A. BudanovaRussian Federation
MD
Yu. N. Belenkov
Russian Federation
I. Ya. Sokolova
Russian Federation
O. N. Antyufeeva
Russian Federation
V. I. Ershov
Russian Federation
I. S. Ilgisonis
Russian Federation
I. Yu. Gadaev
Russian Federation
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374–403. DOI:10.1016/j.ejca.2012.12.027
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768–801. DOI:10.1093/eurheartj/ehw211
3. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy. Oncology. 1996;53(6):461–70. DOI:10.1159/000227621
4. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777
5. Koptev V.D., Pospelova T.I., Tsirendorzhiev D.D. Functional state of vascular endothelium in patients with hematological malignancies before and after polychemotherapy. Siberian journal of Oncology. 2010;4:20–4.
6. Blix ES, Husebekk A. Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies. Leukemia & Lymphoma. 2016;57(12):2752–62. DOI: 10.1080/10428194.2016.1201566
7. Giordano P, Muggeo P, Delvecchio M, Carbonara S, Romano A, Altomare M et al. Endothelial dysfunction and cardiovascular risk factors in childhood acute lymphoblastic leukemia survivors. International Journal of Cardiology. 2017;228:621–7. DOI:10.1016/j.ijcard.2016.11.025
Review
For citations:
Budanova D.A., Belenkov Yu.N., Sokolova I.Ya., Antyufeeva O.N., Ershov V.I., Ilgisonis I.S., Gadaev I.Yu. The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases. Kardiologiia. 2019;59(4):64-66. (In Russ.) https://doi.org/10.18087/cardio.2019.4.10251